Responsibility in Advertising: An Oncologist's View

Publisher Website
Google Scholar
Abstract
To the Editor: I believe that the Journal is contributing to an increase in iatrogenic illness. I do not refer to the formal papers or editorials, but to contributions in the advertising section that escape critical review. Dr. Relman, please take out your scissors!During the past two years the Journal has accepted advertisements from Bristol Laboratories for bleomycin, BCNU, CCNU and, more recently, cis-platinum. All the advertised drugs must have some effect on certain tumors since they have been licensed. However, some of the claims for effectiveness are misleading, with drugs having minimal effects on patient survival. For example, . . .

This publication has 0 references indexed in Scilit: